Phase I trial of ISIS-FGFR4Rx for the treatment of obesity.
Latest Information Update: 21 Dec 2011
At a glance
- Drugs IONIS-FGFR4Rx (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 20 Dec 2011 Status changed from planning to recruiting.
- 10 Jan 2011 New trial record